Silence Therapeutics Statistics

Total Valuation

SLN has a market cap or net worth of $834.41 million. The enterprise value is $645.58 million.

Market Cap	834.41M
Enterprise Value	645.58M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

SLN has 46.80 million shares outstanding. The number of shares has increased by 18.35% in one year.

Current Share Class	n/a
Shares Outstanding	46.80M
Shares Change (YoY)	+18.35%
Shares Change (QoQ)	+6.31%
Owned by Insiders (%)	24.46%
Owned by Institutions (%)	41.39%
Float	26.25M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	32.89
Forward PS	n/a
PB Ratio	5.87
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	28.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.83, with a Debt / Equity ratio of 0.00.

Current Ratio	9.83
Quick Ratio	9.15
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -64.28% and return on invested capital (ROIC) is -48.36%.

Return on Equity (ROE)	-64.28%
Return on Assets (ROA)	-21.54%
Return on Capital (ROIC)	-48.36%
Revenue Per Employee	$207,552
Profits Per Employee	-$464,936
Employee Count	109
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	-8.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +93.80% in the last 52 weeks. The beta is 1.29, so SLN's price volatility has been higher than the market average.

Beta (5Y)	1.29
52-Week Price Change	+93.80%
50-Day Moving Average	18.44
200-Day Moving Average	20.40
Relative Strength Index (RSI)	45.25
Average Volume (20 Days)	128,773

Short Selling Information

Short Interest	334,630
Short Previous Month	312,235
Short % of Shares Out	0.72%
Short % of Float	1.27%
Short Ratio (days to cover)	1.93

Income Statement

In the last 12 months, SLN had revenue of $22.62 million and -$50.68 million in losses. Loss per share was -$1.21.

Revenue	22.62M
Gross Profit	12.76M
Operating Income	-61.26M
Pretax Income	-52.45M
Net Income	-50.68M
EBITDA	-60.86M
EBIT	-61.26M
Loss Per Share	-$1.21

Full Income Statement

Balance Sheet

The company has $189.06 million in cash and $232,538 in debt, giving a net cash position of $188.82 million or $4.03 per share.

Cash & Cash Equivalents	189.06M
Total Debt	232,538
Net Cash	188.82M
Net Cash Per Share	$4.03
Equity (Book Value)	142.19M
Book Value Per Share	3.04
Working Capital	200.23M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$36.71 million and capital expenditures -$111,214, giving a free cash flow of -$37.82 million.

Operating Cash Flow	-36.71M
Capital Expenditures	-111,214
Free Cash Flow	-37.82M
FCF Per Share	-$0.81

Full Cash Flow Statement

Margins

Gross margin is 56.40%, with operating and profit margins of -270.81% and -224.01%.

Gross Margin	56.40%
Operating Margin	-270.81%
Pretax Margin	-259.39%
Profit Margin	-224.01%
EBITDA Margin	-269.02%
EBIT Margin	-270.81%
FCF Margin	-148.14%

Dividends & Yields

SLN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.35%
Shareholder Yield	-18.35%
Earnings Yield	-6.07%
FCF Yield	-4.53%

Analyst Forecast

The average price target for SLN is $61.50, which is 244.92% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$61.50
Price Target Difference	244.92%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SLN has an Altman Z-Score of 1.87 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.87
Piotroski F-Score	3